The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances ...
Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-making RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT ...
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
Hosted on MSN
Certara appoints Jon Resnick as new CEO
Certara ( (CERT)) has provided an update. On December 11, 2025, Certara, a leader in model-informed drug development, announced the appointment of Jon Resnick as the new Chief Executive Officer, ...
BostonGene, the developer of an AI foundation model for tumor and immune biology, has entered a strategic collaboration with ...
Virtual clinical trials and digital twins are emerging approaches to understanding mechanisms of drug responses and drug treatment heterogeneity. With the goal of providing the right drug at the right ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback